

FIGURE 1





Figure 3



0310053 061998 866T90 EE900T60

Figure 4A




Figure 4B






Figure 5A



06100633 061998

Figure 5B



0010063 06198
866790 EE900760

Figure 5C




Figure 5D





Figure 5E



09100633-061998

Figure 5F





Figure 6A



09100633.061998

Figure 6B




Figure 7A





Figure 7B



09100633.061998

Figure 8A




Figure 8B




Fig. 9




Figure 10A





Figure 10B



09100531 061998

Figure 10C






Figure 10D



09100633-061998


Figure 12

1st dimension: Isoelectric focusing



2nd dimension: SDS PAGE

Figure 13




**Phage Display
Library Selection**

FIG. 14

**scFv Array
Immunoassay &
Epitope Mapping**

**Protein-Protein
Interactions**






FIG. 15




FIG. 16




Figure 17





Fig. 18



09100637-061998

FIG. 19




Fig. 19A

Fig. 19B

Fig. 19C

0010063 00" E900T60

FIG. 20




Fig. 20A

Fig. 20B

Fig. 20C

09100631 061998

FIG. 21




Fig. 21A

Fig. 21B

Fig. 21C

Fig. 21D

00100633 061998

FIG. 22




Fig. 22A

Fig. 22B

Fig. 22C

Sample	Protein	Area	Intensity
Disease	Int std	1139.044	3.340518
	marker	695.4804	0.580081
Drug treated	Int std	1383.883	3.780178
	marker	71.05119	0.143227

Fig. 22D

Normalized marker peak area (marker/internal std):

Control	0.0
Disease	0.61
Drug treated	0.05

866T90" E900T60

FIG. 23
Retentate MapTM of Human Urine
SELDI ProteinChipTM Array




FIG. 24




FIG. 25




Fig. 25A

Fig. 25B

866T90" E900T60

FIG. 26




FIG. 27




Fig. 27A

Binding in the absence of free receptor (—)

Binding in the presence of excess free receptor (---)




Fig. 27B

FIG. 28




Fig. 28A




Fig. 28B




Fig. 28C

5000 10000 15000 20000 25000 30000
Molecular weight

09100633 061998

FIG. 29




Fig. 29A




Fig. 29B




Fig. 29 C

Molecular weight

0910063-06198
866T90-EE900T60

Figure 30





Figure 31



09100633-061998

Figure 32




FIG. 33

Fig. 33A

Intensity

Fig. 33B

